Celularity Inc Total Liabilities
Celularity Inc total liabilities. Based on the latest financial reports, Celularity Inc (CELU) has total liabilities worth $134.33 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CELU asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Celularity Inc (2018–2024)
Total liabilities of Celularity Inc from 2018 to 2024. This chart illustrates how Celularity Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Celularity Inc (CELU) investment intensity to see how much of total assets are deployed in long-term investments.
Celularity Inc Competitors by Total Liabilities
The table below lists competitors of Celularity Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hammerson PLC
LSE:HMSO
|
UK | GBX1.73 Billion |
|
CMC Markets PLC
LSE:CMCX
|
UK | GBX550.69 Million |
|
ScandBook Holding AB
ST:SBOK
|
Sweden | Skr188.61 Million |
|
Goldenstone Acquisition Ltd
NASDAQ:GDST
|
USA | $13.63 Million |
|
Globe Industries Corp
TW:1324
|
Taiwan | NT$220.64 Million |
|
Consus Enerji Isletmeciligi ve Hizmetleri AS
IS:CONSE
|
Turkey | TL5.87 Billion |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
Australia | AU$13.30 Million |
|
Sustainable Power & Infrastructure Split Corp
TO:PWI
|
Canada | CA$33.60 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Celularity Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Celularity Inc asset portfolio.
Liquidity & Leverage Metrics
Celularity Inc Total Liabilities Ratios Explained
Celularity Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celularity Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celularity Inc (2018–2024)
The table below shows the annual total liabilities of Celularity Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $123.84 Million | +20.32% |
| 2023-12-31 | $102.93 Million | -49.09% |
| 2022-12-31 | $202.16 Million | -35.76% |
| 2021-12-31 | $314.71 Million | -23.67% |
| 2020-12-31 | $412.30 Million | +7.47% |
| 2019-12-31 | $383.63 Million | +254712.53% |
| 2018-12-31 | $150.56K | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more